Atorvastatin for moderate-to-severe thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether the cholesterol-lowering drug atorvastatin can help people with active, moderate-to-severe thyroid eye disease (swelling and bulging of the eyes caused by an overactive thyroid). You will receive the drug or a placebo alongside your usual steroid treatment, and your eyes will be checked over about a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have moderate-to-severe thyroid eye disease that is active, meaning your eyes are inflamed and bothering you.
- You are expected to need eye decompression surgery after finishing your steroid treatment.
- You can attend weekly infusion visits and complete follow-up for about 11 months.
- You agree to use effective birth control if you can become pregnant, through week 24.
- You have not used any cholesterol-lowering drugs in the past 3 months and do not have a separate medical reason to need them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether atorvastatin (a cholesterol-lowering pill) can improve active, moderate-to-severe Graves’ orbitopathy (eye swelling and bulging). It compares outcomes in people who meet specific safety and disease-activity requirements.
This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.
This trial tests whether a statin (a cholesterol-lowering medicine) combined with vitamin D can improve active thyroid eye disease. It may help if you have both eye inflammation and high cholesterol.
This study tests whether high-dose steroid pulses (given through a vein) can help people with moderate to severe Graves' eye disease that is still active. It is for people who have not yet been treated with steroids and whose eye problems began within the past year.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
This trial tests two different ways of giving a steroid medicine (methylprednisolone) through an IV to treat active Graves' eye disease. The goal is to see which approach works better and is safer for people with moderate to severe symptoms.
Hear when a new Graves Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.